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Osteoarthritis is associated with the irreversible degeneration of articular cartilage. Notably, in this condition, articular cartilage chondrocytes undergo phenotypic and gene expression changes that are reminiscent of their end-stage differentiation in the growth plate during skeletal development 1,2 . Hedgehog (Hh) signaling regulates normal chondrocyte growth and differentiation [3] [4] [5] [6] [7] [8] ; however, the role of Hh signaling in chondrocytes in osteoarthritis is unknown. Here we examine human osteoarthritic samples and mice in which osteoarthritis was surgically induced and find that Hh signaling is activated in osteoarthritis. Using several genetically modified mice, we found that higher levels of Hh signaling in chondrocytes cause a more severe osteoarthritic phenotype. Furthermore, we show in mice and in human cartilage explants that pharmacological or genetic inhibition of Hh signaling reduces the severity of osteoarthritis and that runt-related transcription factor-2 (RUNX2) potentially mediates this process by regulating a disintegrin and metalloproteinase with thrombospondin type 1 motif-5 (ADAMTS5) expression. Together, these findings raise the possibility that Hh blockade can be used as a therapeutic approach to inhibit articular cartilage degeneration.
Osteoarthritis is the most common form of arthritis, affecting over 200 million people worldwide 9 . Currently, there are no pharmacological agents that prevent the degeneration of articular cartilage associated with osteoarthritis. When osteoarthritis develops, articular cartilage chondrocytes undergo cellular changes reminiscent of terminal growth plate chondrocyte differentiation. For instance, they undergo hypertrophy and upregulate expression of COL10A1 (encoding collagen, type X, α1) and MMP13 (encoding matrix metallo-peptidase-13) 1 . Hh signaling has a crucial role in skeletal development, positively regulating chondrocyte differentiation during development and after birth [3] [4] [5] [6] [7] [8] 10 . Indian Hh (Ihh), the major Hh ligand in chondrocytes, binds the Patched-1 (PTCH1) receptor, which releases its inhibition on Smoothened (SMO). SMO can then signal to process the glioma-associated oncogene homolog (GLI) family of transcription family factors, upregulating downstream target genes, which include Hh signaling pathway members GLI1, PTCH1 and HHIP (hedgehog-interacting protein).
To determine whether Hh signaling is activated in osteoarthritis, we examined the expression of the Hh target genes, GLI1, PTCH and HHIP in human osteoarthritic samples obtained from ten subjects undergoing total knee replacement. We assessed the severity of osteoarthritis histologically by the International Cartilage and Repair Society (ICRS) grading scale 11 and by examining the levels of expression of genes known to be expressed in osteoarthritis, namely ADAMTS5, COL10A1, RUNX2 (encoding runt-related transcription factor-2) and MMP13 12, 13 ( Fig. 1 and Supplementary Table  1) . We also induced osteoarthritis in mice by medial meniscectomy in the knee 12 . We characterized six knees in each group at 8 and 16 weeks after meniscectomy. Medial meniscectomy caused substantial changes in ICRS grading (summary score 17.1 versus 4.6, P = 0.003), which was accompanied by over a tenfold increase in the expression of osteoarthritic markers in cartilage microdissected from the underlying bone (16-week time point shown in Fig. 1 and Supplementary Table 1) . We examined the knees by immunohistochemistry for type X collagen as well as for cartilage degradation products: the aggrecan NITEGE neoepitope 14 and the collagen C1, 2C neoepitope 15 , which are epitopes exposed by degradation of aggrecan or of either type I or type II collagen. There was enhanced type X collagen and neoepitope staining of enzymatic degradation products (Supplementary Fig. 1 ). We also examined noncartilaginous tissues in the mouse samples using histology and histomorphometry 16 , which showed subchondral bone changes (Supplementary Table 2 ) and low-grade synovitis, as scored by a previously described method 17 (Supplementary Table 3) , findings typical of noninflammatory arthritis.
We found a significant (P = 0.005) increase in GLI1, PTCH1 and HHIP expression in the human osteoarthritic cartilage, with worse ICRS scoring (summary score 8.0) compared to the less involved samples (summary score 15.2) ( Fig. 1 and Supplementary  Table 1 ). There was also a substantial increase in the expression of the Hh targets, Gli1, Ptch1 and Hhip in articular cartilage in mice in which osteoarthritis was surgically induced (P = 0.005 for the 16-week time point, Fig. 1 Fig. 2) .
We next investigated whether Hh signaling activation predisposes mice to osteoarthritis by examining the joint phenotype of genetically modified mice in which Hh signaling is activated. The Ptch1 +/-mouse harbors a heterozygous null mutation of Ptch1, which results in the upregulation of Hh target genes 18 . The Col2a1-Gli2-transgenic mouse overexpresses the full-length form of the Hh-activated transcriptional factor Gli2 in chondrocytes 19 . We crossed the Gt(ROSA)26Sor tm1(Smo/YFP)Amc mouse, which expresses the constitutively active W539L point mutation of the mouse smoothened protein (SmoM2) upon Cre-mediated recombination, with COL2-rtTA-Cre mice, which express Cre recombinase under Col2a1 regulatory elements (COL2) inducible by doxycycline (rtTA), so that SmoM2 was expressed in chondrocytes when we administered doxycycline 20, 21 . We gave these mice doxycycline at 10 weeks of age. We examined eight mice in each group at 18 weeks of age and 26 weeks of age. We used littermate wild-type mice, or, in the case of mice expressing the conditional Gt(ROSA)26Sor tm1(Smo/YFP)Amc allele, mice not expressing COL2-rtTA-Cre but still treated with doxycycline, as controls. Effective recombination is shown in Supplementary Figure 3 .
Mice showing activation of Hh signaling developed osteoarthritis, as indicated by characteristic radiographic and histological changes (data for 18-week-old mice are shown in Fig. 2) . Moreover, the severity of osteoarthritis, as determined by ICRS scoring (Supplementary Table 1) , expression of genes known to be upregulated in osteoarthritis (Fig. 2c) , and immunostaining for type X collagen and enzymatic cartilage degradation products, positively correlate with the level of Hh activation, as detected by real-time RT-PCR and immunohistochemistry ( Fig. 2c and Supplementary Fig. 1 ). The ICRS summary scores for wild-type littermate controls versus Ptch1 +/− mice were 17.5 versus 14.8 (P = 0.00475), for controls versus Col2a1-Gli2-transgenic mice, 17.1 versus 7.0 (P = 0.0026), and for Gt(ROSA)26Sor tm1(Smo/YFP)Amc mice in which the constitutively active SMO is not expressed compared to mice in which it was activated, 17.2 versus 0.6 (P = 0.0026). In addition to the changes observed in chondrocytes, mice with higher levels of Hh signaling had changes in the subchondral bone similar to those observed in surgically induced osteoarthritis, and they showed an increase in the severity of synovitis (Supplementary Table 3 ). The mice did not show an abnormal growth plate phenotype and had a normal shape to their chondroepiphysis, consistent with previous reported analyses of these mice 22 . We examined the mice for changes in apoptosis and proliferation, using TUNEL and Ki67 staining, respectively, but did not observe any differences (data not shown).
To investigate whether Hh signaling blockade attenuates the severity of osteoarthritis, we examined mice with osteoarthritis induced by arthrotomy and excision of the medial meniscus in the knee. We crossed the Smo tm2Amc mouse, which expresses a null allele of Smo upon exposure to Cre recombinase, with the COL2-rtTA-Cre mouse to generate mice in which a null allele of Smo was expressed upon administration of doxycycline 1 week after surgery, resulting in downregulated Hh signaling in chondrocytes 21, 23 . As a control, we used littermates that do not express COL2-rtTA-Cre but that we still treated with doxycycline. We also blocked Hh signaling pharmacologically 31 H 42 N 4 0 5 ) with a daily intraperitoneal injection starting the week after surgery 24, 25 . There was no premature closure or other gross defects of the growth plate, findings consistent with reports of prolonged Hh signaling dysregulation in mice of a similar age [26] [27] [28] . We assessed the effectiveness of the blockade of Hh signaling by real-time PCR for expression of Gli1, Hhip and Ptch1 ( Fig. 3 and Supplementary Fig. 4 ) and by using immunohistochemistry to detect Ptch1 and Hhip (Supplementary Fig. 2) . We observed the mice at monthly intervals for up to 6 months after surgery, and we examined six to eight mice at each time point in each group. With either genetic inhibition or the use of the pharmacological agent, we found a significant decrease in expression of osteoarthritis markers with Hh signaling blockade (Fig. 3, Supplementary Table 4 and Supplementary  Fig. 4 ). There was a substantial improvement in ICRS scores with Hh blockade (summary score 4.2 for surgery alone versus 13.2 for surgery and pharmacologic blockage, P = 0.0154; and 4.4 for surgery alone versus 12.2 for surgery and genetic blockade, P = 0.0125; data from 6 months of treatment). Hh blockade also resulted in improved bone volume and trabecular thickness (Supplementary Table 2 ) a decrease in the severity of synovitis (Supplementary Table 3 ) and a decrease in the quantity and intensity of immunohistochemical staining for type X collagen, as well as for antibodies to neoepitopes associated with cartilage degradation (Supplementary Fig. 1) .
We next investigated whether Hh signaling modulation could alter osteoarthritis markers in human cartilage samples. We established explant cultures of osteoarthritic cartilage samples from eight subjects and treated them with either Hh ligand or carrier as a control to upregulate Hh signaling or with the pharmacological Hh blocker or carrier for 24 h as previously reported 25 . We verified the effectiveness of Hh modulation by determining the expression l e t t e r S of PTCH1, GLI1 and HHIP target genes, and we also examined markers of osteoarthritis. Upregulation of Hh signaling in human samples resulted in the increase of osteoarthritic markers ADAMTS5, RUNX2, COL10A1 and MMP13 (Fig. 4a) . However, with pharmacological Hh blockade, expression of the same markers was decreased by at least half (Fig. 4b) . We then examined how Hh signaling might regulate the expression of ADAMTS5, which is known to have a key role in osteoarthritis, as its deletion prevents cartilage degradation in mice with surgical removal of their medial meniscus 12 . Examination of the ADAMTS5 promoter 29 did not reveal any GLI consensus binding sequences. However, ADAMTS5 is known to be regulated at the transcriptional level by RUNX2 (ref. 29) , a protein also known to be expressed in osteoarthritis 30 and transcriptionally regulated by Hh signaling 31, 32 . As such, it is possible that Hh signaling regulates the expression of ADAMTS5 by regulating the expression of RUNX2. To test for this possibility, we established primary cell cultures from articular chondrocyte samples as previously described 33 . We transfected them with either an siRNA construct for RUNX2 or a scrambled control and treated them with Hh ligand, the Hh-blocking agent or carrier as a control. Hh positively regulated ADAMTS5 expression in cells expressing the scrambled control, but in cells in which RUNX2 was knocked down, hedgehog did not regulate ADAMTS5 expression (Fig. 4c) .
Here we have shown that Hh signaling is activated in human and mouse osteoarthritis. Moreover, in genetically modified mice, the level of Hh activation positively correlates with the severity of osteoarthritis. Ihh is a mechanoresponsive gene in chondrocytes 34 , and in posttraumatic situations, it could be upregulated owing to abnormal forces on the joint. These forces might be a mechanism causing Hh signaling activation, driving osteoarthritis. Osteoarthritis can also develop from subtle changes in joint shape or in cases of atypical joint morphology, causing abnormal mechanical stresses in the joint. The Ptch1 +/-and Col2a1-Gli2-transgenic mice show Hh signaling activation throughout development, and this could result in subtle changes in joint architecture. However, our data in the COL2-rtTACre;Gt(ROSA)26Sor tm1(Smo/YFP)Amc -transgenic mouse show that activation of Hh signaling in chondrocytes after mice are a few months old also predisposes them to osteoarthritis, suggesting that a change in the joint shape alone is not responsible for the development of osteoarthritis. Hh signaling is crucial in regulating the chondrocyte phenotype towards hypertrophy, both during embryonic The level for expression from control knees was arbitrarily defined as '1', and data for the transgenic mice are given as the mean. The error bars are 95% confidence intervals (n = 6, *P < 0.05). Data from mice at 18 weeks of age are shown.
l e t t e r S development and after birth. This finding may explain why mice with activated Hh signaling in chondrocytes are predisposed to the development of osteoarthritis, as chondrocyte hypertrophy is routinely seen especially in late-stage osteoarthritis, where chondrocytes are unable to maintain the proper extracellular environment for normal joint function 35 . These changes are reminiscent of those that occur in the growth plate, where hypertrophic chondrocytes undergo cell death and are replaced with bone in the process of endochondral ossification. Such a process at the articular surface could lead to the onset of osteoarthritis.
Other pathways also influence the development of the osteoarthritis phenotype, such as the ADAMTS5 pathway. We found that Hh indirectly regulates ADAMTS5, through Hh-mediated expression of RUNX2. Mice deficient in Runx2 also have an osteoarthritis-like phenotype 30 , although the cartilage changes reported in Runx2-deficient mice are not the same as the ones we found with Hh modulation. For instance, there is more of an effect on preservation of cartilage height in mice in which Hh signaling is modulated. During chondrocyte development, Runx2 and Hh have both overlapping and distinct functions 36, 37 . This relationship is probably also the case in osteoarthritis, where some but not all of the effects of Hh modulation are mediated by RUNX2.
We found that inhibition of Hh signaling attenuates the severity of osteoarthritis in mice in vivo, and in human osteoarthritic cartilage explants in vitro. As there are a number of Hh-blocking agents poised for trials in humans 38 , this raises the intriguing possibility that osteoarthritis might be prevented, in part, by treatment with such agents. Toxicity and side effects with Hh-blocking agents are primarily related to development and growth. Because osteoarthritis predominantly occurs in mature individuals, the effects of such drugs would not be as much of a concern. Furthermore, in cartilage regeneration strategies, chondrocytes often develop a hypertrophic phenotype 39 , and inhibition of Hh signaling may also improve outcomes in cartilage repair or tissue engineered therapies. e r r ata & c o r r i g e n d a
